Clinical Trial: Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade II, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.

U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06810726) titled 'Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade II, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.' on Jan. 17.

Brief Summary: The goal of this investigational study is to evaluate the safety and clinical performance of Tropocells Autologous Platelet-rich Fibrin (PRF) for wound care for both males and females, ages 18-80 years old, with Grade 1 and 2, mild to moderate, neuroischemic diabetic chronic foot ulcers in subjects with Type 1 and Type 2 Diabetes Mellitus. The main question[s] it aims to answer [is/are]:

Measure 1: Wound Closure with Tropocells Autologous PRF System for...